Raymond James Trust N.A. Trims Position in Hologic, Inc. (NASDAQ:HOLX)

Raymond James Trust N.A. reduced its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 6.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,817 shares of the medical equipment provider’s stock after selling 187 shares during the period. Raymond James Trust N.A.’s holdings in Hologic were worth $229,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the company. Janus Henderson Group PLC lifted its stake in shares of Hologic by 29.5% in the 1st quarter. Janus Henderson Group PLC now owns 99,707 shares of the medical equipment provider’s stock valued at $7,773,000 after purchasing an additional 22,732 shares during the last quarter. B. Riley Wealth Advisors Inc. lifted its position in Hologic by 13.0% in the first quarter. B. Riley Wealth Advisors Inc. now owns 3,198 shares of the medical equipment provider’s stock valued at $249,000 after buying an additional 367 shares during the last quarter. Tidal Investments LLC boosted its stake in Hologic by 10.8% during the first quarter. Tidal Investments LLC now owns 16,901 shares of the medical equipment provider’s stock worth $1,317,000 after buying an additional 1,654 shares during the period. Comerica Bank increased its position in shares of Hologic by 40.9% during the first quarter. Comerica Bank now owns 110,053 shares of the medical equipment provider’s stock valued at $8,580,000 after acquiring an additional 31,967 shares during the last quarter. Finally, iA Global Asset Management Inc. purchased a new stake in shares of Hologic in the 1st quarter valued at approximately $37,000. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Stock Up 0.6 %

Hologic stock opened at $79.44 on Friday. The stock has a market cap of $18.45 billion, a PE ratio of 23.86, a P/E/G ratio of 2.51 and a beta of 0.98. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03. The stock’s fifty day moving average is $80.28 and its two-hundred day moving average is $78.42. Hologic, Inc. has a 1-year low of $67.59 and a 1-year high of $84.67.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The firm had revenue of $987.90 million during the quarter, compared to the consensus estimate of $978.25 million. During the same period in the prior year, the company posted $0.89 earnings per share. The firm’s quarterly revenue was up 4.5% compared to the same quarter last year. On average, sell-side analysts expect that Hologic, Inc. will post 4.27 EPS for the current fiscal year.

Analysts Set New Price Targets

HOLX has been the subject of several research reports. Needham & Company LLC reiterated a “buy” rating and issued a $90.00 target price on shares of Hologic in a report on Tuesday, October 15th. Royal Bank of Canada boosted their price objective on Hologic from $86.00 to $89.00 and gave the company a “sector perform” rating in a report on Tuesday, November 5th. Evercore ISI raised their target price on Hologic from $78.00 to $82.00 and gave the company an “in-line” rating in a report on Tuesday, October 1st. Citigroup lowered shares of Hologic from a “buy” rating to a “neutral” rating and cut their price target for the stock from $95.00 to $85.00 in a research note on Tuesday, October 1st. Finally, Leerink Partners lowered their price objective on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Four investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, Hologic currently has an average rating of “Moderate Buy” and a consensus target price of $89.91.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.